RECKITT BENCKIS/S (OTCMKTS:RBGLY) was upgraded by equities researchers at UBS Group from a “neutral” rating to a “buy” rating in a research report issued to clients and investors on Monday, The Fly reports.
A number of other research firms have also commented on RBGLY. Barclays reaffirmed an “overweight” rating on shares of RECKITT BENCKIS/S in a research report on Tuesday, June 23rd. Zacks Investment Research raised RECKITT BENCKIS/S from a “hold” rating to a “buy” rating and set a $18.00 price target for the company in a research report on Thursday, May 7th. Jefferies Financial Group raised RECKITT BENCKIS/S from an “underperform” rating to a “hold” rating in a research report on Wednesday, March 18th. Morgan Stanley reaffirmed an “overweight” rating on shares of RECKITT BENCKIS/S in a research report on Monday, June 15th. Finally, JPMorgan Chase & Co. reaffirmed an “overweight” rating on shares of RECKITT BENCKIS/S in a research report on Friday, June 26th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and six have given a buy rating to the company. The stock has an average rating of “Buy” and a consensus price target of $18.00.
Shares of RBGLY stock opened at $18.50 on Monday. The business has a 50-day moving average of $17.61 and a 200 day moving average of $16.41. The stock has a market capitalization of $64.80 billion, a PE ratio of 20.55 and a beta of 0.72. The company has a debt-to-equity ratio of 0.91, a current ratio of 0.56 and a quick ratio of 0.42. RECKITT BENCKIS/S has a 1-year low of $12.76 and a 1-year high of $18.57.
About RECKITT BENCKIS/S
Reckitt Benckiser Group plc manufactures, markets, and sells health, hygiene, and home products. The company offers products for the treatment of analgesic and gastro-intestinal problems, sore throat, cough, pain, and flu, as well as wellness products in sexual wellbeing, footcare, vitamins, and supplements under the Durex, Gaviscon, Nurofen, Mucinex, Scholl/Amopé, and Strepsils brand names.
Further Reading: Stop Order Uses For Individual Investors
Receive News & Ratings for RECKITT BENCKIS/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RECKITT BENCKIS/S and related companies with MarketBeat.com's FREE daily email newsletter.